Acadian Asset Management LLC reduced its position in Xencor, Inc. (NASDAQ:XNCR) by 92.9% during the second quarter, Holdings Channel reports. The firm owned 22,761 shares of the biopharmaceutical company’s stock after selling 300,007 shares during the period. Acadian Asset Management LLC’s holdings in Xencor were worth $480,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the company. Parametric Portfolio Associates LLC boosted its position in shares of Xencor by 0.6% in the first quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock worth $867,000 after buying an additional 209 shares during the period. Clinton Group Inc. boosted its position in shares of Xencor by 4.6% in the first quarter. Clinton Group Inc. now owns 15,987 shares of the biopharmaceutical company’s stock worth $382,000 after buying an additional 700 shares during the period. Adams Diversified Equity Fund Inc. boosted its position in shares of Xencor by 2.9% in the first quarter. Adams Diversified Equity Fund Inc. now owns 28,100 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 800 shares during the period. Falcon Point Capital LLC boosted its position in shares of Xencor by 3.1% in the first quarter. Falcon Point Capital LLC now owns 28,926 shares of the biopharmaceutical company’s stock worth $692,000 after buying an additional 883 shares during the period. Finally, Oxford Asset Management boosted its position in shares of Xencor by 0.8% in the first quarter. Oxford Asset Management now owns 128,693 shares of the biopharmaceutical company’s stock worth $3,078,000 after buying an additional 996 shares during the period. 73.53% of the stock is currently owned by institutional investors and hedge funds.

Xencor, Inc. (NASDAQ XNCR) traded up 0.56% during trading on Monday, hitting $21.50. The stock had a trading volume of 82,517 shares. The stock’s market cap is $1.01 billion. The stock has a 50 day moving average price of $22.61 and a 200-day moving average price of $23.05. Xencor, Inc. has a 12 month low of $18.45 and a 12 month high of $29.38.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.10. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. The firm had revenue of $13.34 million for the quarter, compared to the consensus estimate of $8.15 million. On average, equities analysts predict that Xencor, Inc. will post ($1.17) EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/acadian-asset-management-llc-has-480000-stake-in-xencor-inc-xncr/1486792.html.

A number of brokerages have commented on XNCR. Zacks Investment Research cut Xencor from a “hold” rating to a “sell” rating in a research note on Friday. Canaccord Genuity reissued a “buy” rating and set a $36.00 target price on shares of Xencor in a research note on Tuesday, August 8th. Finally, Wedbush reissued an “outperform” rating and set a $29.00 target price on shares of Xencor in a research note on Friday, June 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $29.33.

In other Xencor news, major shareholder John S. Stafford III purchased 1,500 shares of Xencor stock in a transaction dated Friday, June 16th. The shares were purchased at an average cost of $19.67 per share, for a total transaction of $29,505.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce L. A. Carter sold 2,366 shares of the stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $22.00, for a total value of $52,052.00. Following the completion of the sale, the director now owns 68,578 shares in the company, valued at $1,508,716. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,766 shares of company stock worth $739,408. Company insiders own 4.14% of the company’s stock.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.